Marinomed Biotech announces a new EU-wide patent for the Marinosolv technology platform. “The patent protects Marinosolv as a method for the production of aqueous solutions from insoluble or poorly soluble therapeutically or cosmetically relevant active ingredients,” said the Austrian biotech company on Wednesday.
“With this technology, active ingredients reach the target tissue better, which is a central challenge in pharmaceutical development. Targeted release of the active ingredient has proven to be particularly difficult, particularly in tissues where a high local but low systemic concentration of the active ingredient is important, such as eyes, nose and other mucous membranes, ”says Andreas Grassauer, CEO of Marinomed. “Our technology is also extremely interesting for corporate customers, as they can patent active ingredients with expired patent protection as a new formulation using Marinosolv technology,” says the manager.
Livestream on December 14th, 2020 from 6 p.m .:
With Hans-Werner Sinn, former President of the Ifo Institute: Corona and the miraculous increase in money in Europe
– Here is the stream! –